-
Product Insights
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) - Drugs In Development, 2023’, provides an overview of the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Dronabinol) in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Dronabinol) in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Dronabinol) in Epilepsy Drug Details: CannEpil, a fixed-dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Insomnia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabis CINV in Seizures
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabis CINV in Seizures report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabis CINV in Seizures Drug Details: Cannabis CINV is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Cannabinol + Tetrahydrocannabinol) in Pain Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EPI-004 in Cancer Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EPI-004 in Cancer Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EPI-004 in Cancer PainDrug Details:EPI-004 is under development for the treatment of chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Dronabinol) in Epilepsy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Dronabinol) in Epilepsy Drug Details: CannEpil, a fixed-dose combination of tetrahydrocannabinol (THC) and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EPI-006 in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EPI-006 in Opium (Opioid) Addiction report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Dronabinol) in Sedation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Dronabinol) in Sedation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Cannabidiol + Dronabinol) in Sedation Drug Details:CannEpil, a fixed-dose combination of tetrahydrocannabinol...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APIRx-1602 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APIRx-1602 in Psoriasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APIRx-1602 in Psoriasis Drug Details: APIRx-1602 (AX-1602) is under development for the...